April 22, 2015
The government should alleviate companies’ post-marketing regulatory burdens for intractable disease treatments if it is to encourage their development, a representative of the Japan Pharmaceutical Manufacturers Association (JPMA) told a health ministry panel on April 21. Osamu Inagaki, head of...read more